BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29054602)

  • 1. STAT1 Gain-of-Function and Dominant Negative STAT3 Mutations Impair IL-17 and IL-22 Immunity Associated with CMC.
    Hiller J; Hagl B; Effner R; Puel A; Schaller M; Mascher B; Eyerich S; Eyerich K; Jansson AF; Ring J; Casanova JL; Renner ED; Traidl-Hoffmann C
    J Invest Dermatol; 2018 Mar; 138(3):711-714. PubMed ID: 29054602
    [No Abstract]   [Full Text] [Related]  

  • 2. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).
    Zheng J; van de Veerdonk FL; Crossland KL; Smeekens SP; Chan CM; Al Shehri T; Abinun M; Gennery AR; Mann J; Lendrem DW; Netea MG; Rowan AD; Lilic D
    Eur J Immunol; 2015 Oct; 45(10):2834-46. PubMed ID: 26255980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.
    van de Veerdonk FL; Plantinga TS; Hoischen A; Smeekens SP; Joosten LA; Gilissen C; Arts P; Rosentul DC; Carmichael AJ; Smits-van der Graaf CA; Kullberg BJ; van der Meer JW; Lilic D; Veltman JA; Netea MG
    N Engl J Med; 2011 Jul; 365(1):54-61. PubMed ID: 21714643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
    Liu L; Okada S; Kong XF; Kreins AY; Cypowyj S; Abhyankar A; Toubiana J; Itan Y; Audry M; Nitschke P; Masson C; Toth B; Flatot J; Migaud M; Chrabieh M; Kochetkov T; Bolze A; Borghesi A; Toulon A; Hiller J; Eyerich S; Eyerich K; Gulácsy V; Chernyshova L; Chernyshov V; Bondarenko A; Grimaldo RM; Blancas-Galicia L; Beas IM; Roesler J; Magdorf K; Engelhard D; Thumerelle C; Burgel PR; Hoernes M; Drexel B; Seger R; Kusuma T; Jansson AF; Sawalle-Belohradsky J; Belohradsky B; Jouanguy E; Bustamante J; Bué M; Karin N; Wildbaum G; Bodemer C; Lortholary O; Fischer A; Blanche S; Al-Muhsen S; Reichenbach J; Kobayashi M; Rosales FE; Lozano CT; Kilic SS; Oleastro M; Etzioni A; Traidl-Hoffmann C; Renner ED; Abel L; Picard C; Maródi L; Boisson-Dupuis S; Puel A; Casanova JL
    J Exp Med; 2011 Aug; 208(8):1635-48. PubMed ID: 21727188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis.
    Kisand K; Peterson P
    Curr Opin Pediatr; 2013 Dec; 25(6):715-21. PubMed ID: 24240291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis.
    Rösler B; Wang X; Keating ST; Joosten LAB; Netea MG; van de Veerdonk FL
    Clin Exp Immunol; 2018 Nov; 194(2):205-219. PubMed ID: 30069986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis.
    Martinez-Martinez L; Martinez-Saavedra MT; Fuentes-Prior P; Barnadas M; Rubiales MV; Noda J; Badell I; Rodríguez-Gallego C; de la Calle-Martin O
    Mol Immunol; 2015 Dec; 68(2 Pt C):597-605. PubMed ID: 26514428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneaous candidiasis.
    Ifrim DC; Quintin J; Meerstein-Kessel L; Plantinga TS; Joosten LA; van der Meer JW; van de Veerdonk FL; Netea MG
    Clin Exp Immunol; 2015 Sep; 181(3):434-40. PubMed ID: 25880788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion.
    Wildbaum G; Shahar E; Katz R; Karin N; Etzioni A; Pollack S
    J Allergy Clin Immunol; 2013 Sep; 132(3):761-764. PubMed ID: 23791509
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment options for chronic mucocutaneous candidiasis.
    van de Veerdonk FL; Netea MG
    J Infect; 2016 Jul; 72 Suppl():S56-60. PubMed ID: 27161991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.
    Egri N; Esteve-Solé A; Deyà-Martínez À; Ortiz de Landazuri I; Vlagea A; García AP; Cardozo C; Garcia-Vidal C; Bartolomé CS; Español-Rego M; Yiyi L; Bosch-Amate X; Ferrando J; Yagüe J; Juan M; Alsina L
    Allergol Immunopathol (Madr); 2021; 49(1):118-127. PubMed ID: 33528939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody.
    Yamazaki Y; Yamada M; Kawai T; Morio T; Onodera M; Ueki M; Watanabe N; Takada H; Takezaki S; Chida N; Kobayashi I; Ariga T
    J Immunol; 2014 Nov; 193(10):4880-7. PubMed ID: 25288569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of two STAT1 gain-of-function mutations in two Iranian families with autosomal dominant chronic mucocutaneous candidiasis.
    Ostadi V; Sherkat R; Migaud M; Modaressadeghi SM; Casanova JL; Puel A; Nekooie-Marnany N; Ganjalikhani-Hakemi M
    Med Mycol; 2021 Feb; 59(2):180-188. PubMed ID: 32526033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel
    Erdős M; Jakobicz E; Soltész B; Tóth B; Bata-Csörgő Z; Maródi L
    Front Immunol; 2020; 11():967. PubMed ID: 32547544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis.
    Smeekens SP; Plantinga TS; van de Veerdonk FL; Heinhuis B; Hoischen A; Joosten LA; Arkwright PD; Gennery A; Kullberg BJ; Veltman JA; Lilic D; van der Meer JW; Netea MG
    PLoS One; 2011; 6(12):e29248. PubMed ID: 22195034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CMCD: Chronic Mucocutaneous Candidiasis Disease].
    Okada S
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):109-117. PubMed ID: 28603201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolving View of IL-17-Mediated Immunity in Defense Against Mucocutaneous Candidiasis in Humans.
    Soltész B; Tóth B; Sarkadi AK; Erdős M; Maródi L
    Int Rev Immunol; 2015; 34(4):348-63. PubMed ID: 26154078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic mucocutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility.
    Dhalla F; Fox H; Davenport EE; Sadler R; Anzilotti C; van Schouwenburg PA; Ferry B; Chapel H; Knight JC; Patel SY
    Clin Exp Immunol; 2016 May; 184(2):216-27. PubMed ID: 26621323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1.
    Carey B; Lambourne J; Porter S; Hodgson T
    Oral Dis; 2019 Apr; 25(3):684-692. PubMed ID: 29702748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TH17 deficiency in human disease.
    McDonald DR
    J Allergy Clin Immunol; 2012 Jun; 129(6):1429-35; quiz 1436-7. PubMed ID: 22554706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.